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ABSTRACT
P-Cadherin is a member of the cadherin family of cell 
surface glycoproteins that mediate Ca2+-dependent cell-cell 
adhesion and is expressed in a differential fashion in normal 
epithelial tissues. The expression of P-cadherin in human 
prostate cancer development has not been investigated pre­
viously. By immunohistochemistry, we show that P-cadherin 
expression is restricted to the cell-cell border of basal epi­
thelial cells in 30 normal prostate samples. This staining is 
down-regulated in prostatic intraepithelial neoplasia and is 
absent in all 25 of the well to poorly differentiated prostate 
cancer specimens analyzed. To examine potential P-cad- 
herin-regulatory elements, we sequenced the 5r-flanking re­
gion of this gene. Similar to the mouse gene, the human 
P-cadherin promoter is TATA-less, contains an Sp-l bind­
ing site and, analogous to the human E-cadherin sequence, 
demonstrates a GC-rich region characteristic of a CpG 
island. Cytosine methylation of this region occurs in 
P-cadherin-negative prostate cancer cell lines but not in cell 
lines expressing this gene. In vivo, a lack of expression in 12 
clinical prostate cancer specimens is not associated with 
methylation of the P-cadherin promoter. These results dem­
onstrate that the expression of the marker
P-cadherin is lost in prostate cancer development and that in
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vivo mechanisms other than cytosine methylation 
this consistent loss of expression.
INTRODUCTION
Cadherins are cell-cell adhesion molecules that form im-
intercellular junctional structures andC a 2  4
play an essential 
maintenance of ar organs (I , 2). During embryogen- 
esis, cellular expression of specific cadherins results in ho- 
mophilie interactions that are critical in the processes of cell 
sorting and tissue stratification (3-5). Alterations in these cel­
lular attachments play a permissive role in the disassociation of  
cells and may modify the carefully regulated differentiation 
processes in epithelial structures (2, 6 -8 ) . For this reason, the 
functional loss of cadherin expression and the molecular mech­
anisms underlying the control of these genes have been impli­
cated in malignant progression (9).
The cadherin family is subdivided into various types, in­
cluding E-, P-, and N-eadherin, with each cadherin class dem­
onstrating a unique tissue distribution (2). Although E-cadherin 
is expressed in virtually all epithelial tissues, the expression of 
P-cadherin is restricted to the basal or lower layers o f stratified 
epithelia in selected organs, including breast and skin (7,10). In
on an sues, a
basal pattern lor P-e m was by
Shimoyama et til. (10) in the prostate. This organization of 
cadherin expression suggests that, in addition to maintaining 
cellular adhesion, P-cadherin may also have other undefined
( I I ). A
, with a loss of the
functions important in differentiation and 
disruption of the normal epithelial archi
basal epithelial cell layer, is histologically diagnostic for pros­
tate cancer, and has been demonstrated to he frequently associ­
ated with a down-regulation in the expression of E-cadherin 
(12). This differential pattern of E-cadherin expression in pros-
t« I f  i \  i  %  »e with the frequent loss o f  the 
us to investigatebasal epithelial layer, 
expression in prostate cancers.
A comparison of the primary structure of human K- and 
P-cadherin demonstrates a 58% homology in their amino acid 
sequences and eolinear organization with unique extracellular 
domains (13). The 5 '-flanking sequence of the H-cadherin gene 
has recently been sequenced and found to be extremely GO 
enriched, meeting the criteria for a “CpG island” (14, 15). 
Aberrant methylation across the CpG island located in the 
promoter region of E-cadherin and
in a selective inactivation of transcription (16, 17). 
of E-cadherin has recently been demonstrated in 
other cancer cell lines, as well as in breast cancer
and an jrentialed prostate cancer specimen (17).
functional block of E-cadherin expression is removed with 
exposure of cell lines to demethylating agents in v i tro .  Addi­
tional factors within the E-cadherin gene that appear important 
to transcriptional regulation include a palindromic sequence
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E-pal (which comprises two E boxes) and an Sp-l binding site
(15, 18).
Isolation of the 5'-FIanking Sequences of the Human 
P-Cadherin Gene. Using pPCad-MVl-HPl (containing the
In this study, we document the normal expression of most 5' 172 bp of the human P-cadherin cDNA; Ref. 21) as a
P-cadherin in a series of prostate tissues and test the hypothesis 
that P-cadherin expression is down-regulated during the devel­
opment of prostate cancer. To investigate the loss of P-cadherin 
expression in cancer specimens, we explore possible mecha­
nisms for the transcriptional control of this gene by sequencing 
the P-cadherin 5 '-flanking region and characterize the methyl­
ation status of a CpG island within this promoter region.
MATERIALS AND METHODS
Prostate Samples and Establishment of Cultures.
Prostatectomy samples were obtained at surgery from men ages 
5 4 -6 8  who had been diagnosed with cancer. Portions of each 
tumor, surrounding normal peripheral prostate tissue, and peri­
urethral benign prostate hyperplasia specimens were frozen im-
at — 70°C for DNA and RNA analysis. Frozen sec­
tions were stained with H&E for histological evaluation of each 
tissue specimen. In the case of tumor tissue, tissue blocks were 
trimmed to yield samples containing 5:70% tumor nuclei. Cul­
tured prostate cancer cell lines LNCaP, Du 145, PC3, and PPC1 
were obtained from the American Type Culture Collection. 
DuPRO and TSU-PR1 were obtained from other sources (19).
Immunohistochemistry and Immunofluorescence
Staining. Frozen prostate specimens were sectioned, 
mounted, and fixed in 100% ethanol for 5 min at room temper­
ature. After rinsing (three times for 2 min each) in TNC buffer 
[10 mM TRIS, 150 mM NaCl, and 2 niM CaCl2 (pH 7.4)], the 
sections were incubated for 1 h (25°C) with mouse monoclonal 
antibody against P-cadherin (20). Anti-P-cadherin was diluted 
1:10 in 3.75% BSA/TNC buffer. After washes with TNC buffer 
(three times for 2 min each), sections were incubated with a 
biotinylated secondary antibody (goat antimouse IgG; Zymed 
Laboratories, Inc., San Francisco, CA) for 30 min. Slides were 
rinsed with TNC buffer (three times for 1 min each) and con-
jugated with a streptavidin-peroxidase c 2x (Zymed) for 15
min. After washing in TNC (three times for 1 min each), 
staining was developed with an aminoethyl carbazole chroma- 
gen substrate (Zymed) in 0.006% peroxide-containing buffer for 
30 min, followed by rinsing with tap water (three times). As a
mouse serum at a dilution of 1:100 as
counterstained with
negative control, we 
a primary í
hematoxylin, dehydrated, and mounted.
To analyze immunofluorescence staining of cell lines, we
• microscgenerated semi-confluent cultures on two-chi 
slides (Nunc Inc., Naperville, IL). The medium was removed, 
and cells were fixed in 100% ethanol for 5 min at room tem­
perature. Rinsing with TNC buffer (three times for 2 min), 
blocking, and incubation with the primary P-cadherin antibody 
at a dilution of 1:10 (at 4°C) were performed as above. After 
rinsing, the secondary antibody, a rhodamine-conjugated (tetra- 
methylrhodamine isothiocyanate) donkey antimouse IgG (Jack­
son ImmunoResearch Laboratories Inc., West Grove, PA) was 
applied and incubated at 4°C for 1 h. After rinsing with TNC, 
slides were treated with SlowFade antifade kit (Molecular 
Probes, Inc., Eugene, OR) and mounted.
probe, a human fetal brain cosmid (Stratagene) was
screened according to Bussemakers et a l  (14) and Sambrook et al. 
(22). Positive clones were selected, and their DNA was digested 
with £coRI. DNA sequences were determined and edited using 
IntelliGenetics computer software. Computer comparison studies 
were performed using sequences obtained from the European Mo­
lecular Biology Laboratory and GenBank nucleotide sequence da­
tabases using CAMMSA computer software (23).
Southern Analysis of P-Cadherin Methylation. Tumor 
and normal prostate DNAs (8 |xg) were digested sequentially with 
the methylation-sensitive enzymes Smal, HueII, or Thai (10 units/ 
|xg) and the methylation-insensitive enzyme BamWl (10 units/|xg; 
New England Biolabs, Beverly, MA) overnight. The digest was 
then electrophoresed on a 1.2% vertical agarose gel and transferred 
to a Hybond N +  nylon membrane (Amersham Corp.) for Southern 
blot analysis. After UV crosslinking (Stratagene), filters were hy­
bridized overnight at 62°C in 10 ml of 1% SDS, 1 m NaCl, 10% 
dextran sulfate, and 0.5 mg alkali-sheared salmon sperm with 
0.5-1.0 X 106 cpm/ml [32P]dCTP random-primed (Amersham) 
604-bp DNA probe generated from the 5'-P-cadherin sequence 
(63% GC rich) designated PCad5'. Primers to generate this probe 
were chosen from the 5'-flanking sequence and included 5'-ACG 
GGA GGT GGA GAA AGA G-3' (sense) and 5'-ACG GCG 
AGG CTG TGG AGT A-3' (antisense). Conditions for this P- 
cadherin amplification included 35 cycles of 95°C for 1 min, 61°C 
for 30 s, and 72°C for 30 s, followed by incubation at 72°C for 5 
min. An additional smaller probe, PCadHAE (320 bp), was gen­
erated by digesting the full-length probe with Had  I. After hybrid­
ization, the blots were washed at 65°C with 0.1X SSC-0.5% 
saline-sodium phosphate-EDTA for approximately 10-20 min. 
Autoradiographs were generated after exposure to radiographic 
film overnight (Kodak). Experiments were repeated in duplicate, 
additional enzyme did not alter the methylated signal, and blots 
were reprobed with additional genes known to be unmethylated to 
confirm complete enzyme digestion.
RT-PCR4 for P-Cadherin Expression. To evaluate 
P-cadherin reexpression, the demethylating agent 5'-deoxy- 
zacytidine (0.5-10 |am) was added to ~50%  confluent cell 
cultures, redosed at days 2 and 4, and harvested at day 5 for 
RNA as described previously (24). Longer-term LNCaP cultures 
(6  months) at a dose of 2  jxm  were established and also analyzed. 
Primers used for cDNA amplification of P-cadherin included 
5 '-TCT CGC GTC TCT CCT CCT TCT-3' (sense) and 5'-GCC 
TGT GCT CCG GTC, AAT TG-3' (antisense) at an annealing 
temperature of 58°C for 30 cycles. (3-Actin primers (Stratagene) 
were used as a control.
RESULTS
Expression of P-Cadherm Protein in Normal Prostate and 
Tumor Samples. To characterize P-cadherin expression in the 
prostate, immunohistochemistry was performed on 30 histolog-
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4 The abbreviations used are: RT-PCR, reverse transcription-PCR; PIN, 
prostatic intraepithelial neoplasia.
■(OOfrX
•uojiuaiiiuSmu '.PH) Jaau«a oí josjnaajd t? paiapisuoo '(pimiMOjjo) suo|saj n icj aptuS-qSiq ui pajou si luaiisd Suiuinis pajdtusip ‘snomiiiuoasip 
11 J  ‘((Xtt’ X *uojjb3¡j|u8bui :p im¡Moj,w)  pu»|S janunn aa pnSau -uu aqpso-j b oí maaBfpB (m o j j o ) snupB jbuuou ‘aAtjisod-uuaqpBa-d 13 8u|/v\oqs
onssii oi«)S(ud j o  uoipas v  ' ( ( ) 9 |  x  ‘ uoiiBaijjuSnm) a|dums .miran ajnjsojd p o i B p u a j a j j i p  Xpnuapoiu b u io jj  ajaq UMoqs ‘s|po muoiuannouapn apisojd 
ui paiBJis'iioiuap si fHiiupris jo sso| op|duion 'p *pdAjasqo s¡ uroi&iaiunoa .raapnu Xjuo :|CMiuoa Xpoqptra ¿ .lB iu u d  smimi \> •uoissajdxa autuquiaui 
uuaqpna-jj jo  niisijapBjBtp *aau«JuaddB paquioa<Cauoq b «[bbaoi (()()f x ) ja/wod jaqSiq *mvm/ ‘.(091 x ) sjaXBj <Oop.pas‘ pira písnq aqi qjoq uj lunipqjida 
aip )noi|f?no.u|j uiasaid si futuinjs ‘Xpoqpira uuaqpiin-g-pira ip iM  paupíjs’ anssij apisojd puiuou jo  uopaas « u¡ *uos[.raduioa Áq '</ •(p im /M o j j i )) 
jatòij ijaa pn pipi da Xjoiajaas aaddn aqi ui Sujupijs jo  aauasqB piti? (Moxin)  jaKw| |jaa (Bipqjrda |BSBq aqj oj uoijBZi|Bao| p u is  sjBaAaj (0 ()l?x) 
jaMod aaqSiq ’¡.m u  ‘.(091 x  ‘uopBoyuiStmi) ajBjsojd aqi jo  unnn iCiopjnos iireuSipniiuou ui XtiAipnajounuiuii uijaqpsa-d .1°  Jatòq pisnq snonuiiuoa 
3Ap¡sod jo iiojjBJisnii! •/> 'Niel 11 ¡ puB uanuBo aimsiud ui ‘aiBjsiud tmunq ijnpB puiuou aqj ui uuaqpno-j jo 3 uiu;nis iBaiuiaqoojsiqounuiiiii / '¡t}¿¡
• 1
C Ztrqa iBasay p o u b o  p ^ i u id
I >r\M J
2124 P-Cadherin Expression Is Lost in Prostate Cancer
•  r  . ------w  r*  .
- I  ,  i I * -  -  r
F ib. Analysis of P-cadherin protein in prostate cancer cell lines by i
positive staining patterns, demonstrating focal increase in protein staining at 
P-cadherin staining. Magnification, X400.
:e staining. Cell lines Du 145 (a), PPC1 
s of cell-cell contact. LNCaP cells (cl) are c
3 (c) s
negative for
normal basal epithelial staining as described 
above. Specimens containing high-grade PIN, considered a pre­
cursor to prostate carcinoma (25), demonstrated a discontinuous 
pattern o f basal layer staining with scattered positive-staining 
cells (Fig. If).
Using immunofluorescence, an analysis of a series of prostate 
cancer cell lines derived from metastatic lesions was performed. No 
protein expression of P-cadherin by immunofluorescence was 
noted in cell lines LNCaP, TSU-PR1, and DuPRO (Fig. 2 and data 
not shown). However, cell lines PC3, Dul45, and PPC1 (Fig. 2) 
revealed a continuous staining of the cell membrane with an ac­
centuation of immunostaining at points of cell-cell contact. Mini­
mal staining heterogeneity was noted in these cultures. RT-PCR on 
these prostate cancer cell lines confirmed these findings (data not 
shown). We have demonstrated previously by Western blotting that 
normal prostate epithelial cells in culture express P-cadherin at 
moderate levels similar to the level observed in PC-3 (19). When 
stained in culture, normal prostate 
staining pattern for P-cadherin expression similar to the pattern 
observed for DU 145 cells.
Sequence of the 5' Human P-Cadherin Gene. To ex­
amine possible mechanisms for the transcriptional regulation of 
P-cadherin expression in the prostate, we sequenced the 5'-
flanking r m ; human P-cadherin gene. A  human fetal
brain cosmid library was screened with pPCad-MVl-HPl, and
was isolated. A 2.5-kb £W>RI fragment 
of clone cHPC8 was found to contain the 5 '-end of the previ­
ously characterized human P-cadherin cDNA (21).
Comparison of the immediate 5 '-flanking sequences of the 
human P-cadherin gene (GenBank accession number X95824) 
with those reported for the mouse P-cadherin gene promoter (26, 
27) reveals a 73% homology. There is conservation of a 
CCAAT box (at -6 4 ) ,  with no TATA box. In the human 
P-cadherin promoter, three E boxes are present (helix-loop-helix 
binding motif; R ef 18), compared to two found in the mouse. A 
putative Sp-l binding site (—88) is also conserved. The probable 
initiation site for transcription is 70 nucleotides upstream of the 
translation start site based on a comparison with the mouse 
sequence (27). An Alu repeat is present approximately 700 bp 
upstream from the translation start site.
Methylation and Expression of P-Cadhcrin in Normal 
Prostate, Primary Prostate Cancers, and Cell Lines. The P~ 
cadherin gene contains a CpG island 5' and extending into the
first exon on the basis of several criteria, including a G and 
C content of 73%, a CG:GC ratio o f greater than 0.6, and 
extension of this island over more than 500 bp (Ref. 28; Fig. 
3A). Restriction with the methylation-insensitive restriction 
enzyme BamlAl provides a flanking cut for this region. Di­
gestion with the methylation-sensitive enzymes Thai and 
HaeII revealed methylation in the LNCaP, TSU-PRl, and 
DuPRO prostate cancer cell lines at sites located around the 
CpG island promoter elements in the 5 '-flanking region, 
using both probes PCad5' and the truncated version, 
PCad/Zflell (Fig. 35). Sites upstream from the putative tran­
scription start site were completely methylated in LNCaP and 
partially in TSU-PRl and DuPRO (see Table 1). However, in 
these three cell lines, the Smal as well as the HaeII and Thai 
methyl-sensitive sites in close proximity to the transcription 
start site (within 50 bp on either side) were never methylated. 
Indeed, complete methylation across this region was never 
seen. No methylation of any site is demonstrated in Du 145, 
PC3, or PPC1 cell lines.
Aberrant methylation o f GC-rich promoter regions has 
been demonstrated to correlate with transcriptional inactivation 
for a number of specific genes (16). The detection of any 
methylation within the P-cadherin promoter region CpG island 
(£>.#., TSU-PRl, DuPRO, or LNCaP) is always associated with 
transcriptional inactivation by both RT-PCR (data not shown) 
and immunohistochemistry (Fig. 2). Cell lines expressing de­
tectable P-cadherin message or protein, including Du 145, PC3, 
and PPC I, are unmethylated at all restriction sites analyzed. 
Treatment of the cell lines TSU-PRl and LNCaP with 5-aza-2- 
deoxycytidine and 5-azacytidine, both demethylating agents, 
fail to reexpress P-cadherin message by RT-PCR (data not 
shown). Both short-term exposure (3 days) and longer dosing 
for 6 months did not reactivate P-cadherin, although glutathione 
■S’-transferase-ir, which is methylated extensively in LNCaP 
(29), was reactivated in this long-term culture.5
The methylation status o f this CpG island was examined in 
a series of 12 normal and matched primary prostate cancers 
using the methylation-sensitive enzymes Thai, HaeII (Fig. 3C), 
and Smal (data not shown). All of these restriction sites were
W, G. Nelson, personal communication.
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Fig. 3 Restriction map and Southern blot méthylation analysis of P-cadherin in prostate cancer cell lines and tumor samples. A, the restriction enzyme 
map and CG dinucleotide density of the 5' promoter region of P-cadherin. Exon 1 is encompassed by a 1.9-kb BainHMkxnkmg restriction fragment, 
which includes the 1-kb promoter CpG island. The density of CG dinucleotides in the 930-bp flanking sequence and 3' downstream gene is shown 
below the sequence. Note the increase in CpG density across exon 1 and the promoter region. Méthylation analysis is performed by digestion with 
the methyl-sensitive enzymes Thai (four sites), Haell  (three sites), or Smal (one site). The sequence spanned by the probes PCad5' and ?-Ci\dHaell 
(used for Southern analysis) are shown. B, méthylation analysis of the 5 '-CpG island in cultured prostate cancer cell lines. All restrictions were 
performed with 10 units/|Jig DNA. *, méthylation bands. A Bamlil  “flanking” cut (Lane I ) and blood DNA (Lane 2) are controls. Cell lines Du 145 
(¿¿mt' J ), PC3 (Lane 5), and PPC-1 (Lane S) are unmethylated (464-bp band) and express the P-cadherin gene. In contrast, LNCaP (Lane 4 ), TSU-PRl 
(Lane 6), and Du PRO (Lane 7) are methylated (see Table 1) and do not express the P-cadherin gene. Complete méthylation to 1.9 kb across this CpG 
island was not observed. O  Southern blots generated using Thai and Haell. Paired prostate tumor samples (T) and normal prostate tissues (A0 from 
three patients demonstrate no méthylation. The left panel was probed with PCad5' and the right with probe PCixdHaell (see map shown in A).
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found to be unmethylated in normal tissues, including blood and DISCUSSION
normal prostate. Although these prostate cancers were negative 
for P-cadherin protein by immunohistochemical staining (see
\ t f
The expression of the cell adhesion molecules, the cad- 
herins, appears to play an essential role in the stabilization and
tumor sample. No deletions of this region were detected using maintenance of nonmalignant differentiated tissues. In the pres- 
this 5' P-eadherin-specific probe. ent study, we demonstrate that P-cadherin is expressed in the
in any
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basal epithelial layer o f the acinar ducts in all 30 normal prostate 
tissues examined. No stromal expression is noted. Benign pros­
tatic hyperplasia specimens reveal a similar immunohislochem- 
ical staining pattern. This immunostaining accumulates in re­
gions of cell-cell apposition in a manner similar to the 
expression of other classical cadherins, including E-cadherin 
(10). However, E-cadherin is expressed in all epithelial layers 
(12), a fact that suggests profoundly different roles for these two 
closely related cadherins. The prostate epithelium is multilay­
ered, with a subset of prostate basal cells functioning most likely 
as stem cells that give rise to ductilar secretory epithelial cells 
(30-32). During breast development, P-cadherin appears to play 
a fundamental morphoregulatory role as evidenced by its selec­
tive expression in the cap cells of budding ductules (11). Thus, 
segregation of P-cadherin in the basal layer of the prostate and 
other tissues (7, 10) suggests a potential role for this gene in the 
regulation o f epithelial intercellular junctional adhesion, as well 
as in the critical process of secretory cell differentiation.
Progression to histological prostate cancer is characterized 
by profound alterations in intercellular and cell-substratum in­
teractions. These include a disruption of the normal glandular 
epithelial hierarchy and the development of dysplastic ductules 
lined by a single layer of pleomorphic cells. P-cadherin protein 
expression is clearly absent in all 25 well to poorly differenti­
ated (Gleason 4 -9 ) primary prostatic adenocarcinomas as­
sessed. Furthermore, an incremental decrease in P-cadherin 
staining is noted during the transition from a normal acinar 
gland to PIN, believed to be a preneoplastic lesion (25). This 
striking absence of P-cadherin in histological prostate cancer 
occurs more frequently and is less heterogeneous than alter­
ations in staining seen with the panepithelial marker E-cadherin 
( 1 2 ).
The loss of P-cadherin immunostaining is not a universal 
finding in other tumor systems and does not occur to the 
complete extent that we demonstrate in prostate specimens. 
Only subsets of breast, lung, and gastric cancers have been 
found to be negative (10, 33-35). No clear correlation is seen 
with histology, grade, or prognosis in these studies, although 
several have suggested that a reduction in expression occurs 
with progression to a less-differentiated histology (33, 36). 
These data suggest that the regulation o f P-cadherin in these 
tumor systems may involve several tissue-specific transcrip­
tional mechanisms. Cytokines appear to up-regulate P-cadherin 
in PC3 prostate cancer cells (37). With regard to deletional 
events at 16q22, a region that encompasses both the E- and 
P-cadherin genes, a loss of heterozygosity is seen in ~30%  of  
primary prostate cancers (38). No mutational 
P-cadherin have been published to date.
Human E-cadherin transcriptional regulation has
E-cadherin promoter (14), the putative transcription start site for 
P-cadherin (based on a comparison with the mouse promoter; 
Ref. 27) lies within a GC-rich region (>70% ) that fulfills all of 
the criteria for a CpG island (28). Additional 5' sequences and 
studies using promoter constructs should confirm this transcrip­
tion start site and the role these promoter elements play in 
P-cadherin transcription.
The finding of a CpG island in the promoter region 
prompted an investigation of DNA méthylation in prostate can­
cer cell lines and tissues. Méthylation appears to be a mecha­
nism important in the transcriptional control o f the E-cadherin 
gene in vivo and in vitro (17). Prostate cancer cell lines express-
unmethylated at alling P-cadherin are found to be c 
CG sites within this island. We have 
ablation of transcriptional activity when hypermethylation is 
present to any extent within this GC-rich promoter region. 
Several interesting observations were made: (a ) the presence of 
incomplete méthylation within this 5'-CG-rich region was also 
associated with transcriptional loss. Whether this represents a 
heterogeneous cellular population or monoallelic méthylation is 
unknown; (b) we note that méthylation appeared to involve CG 
dinucleotide sites located peripherally in this island more fre­
quently than sites directly adjacent to the putative transcription 
start site (see Table 1). It has recently been hypothesized by 
Graff et al. (41) that the aberrant neoplasia-associated méthyl­
ation of CpG islands spreads from outside CG-rich regions 
inward, possibly from Alu sites that often contain méthylation; 
(c) extensive culture with several demethylating agents was not 
capable of selectively reactivating P-cadherin transcription in 
vitro. This observation suggests that hypermethylation is not 
involved directly in the inactivation of P-cadherin expression in 
these prostate cancer cell lines; and (d) the examination of 12 
P-cadherin protein-negative prostate tumors reveal no 
of méthylation in vivo. This would suggest that these hyper­
methylation events represent an in vitro phenomenon, 
talized cell lines demonstrate frequent CpG island 
(~ 50 -70%  CpG islands methylated; 42), and this may reflect
mechanisms for protecting inactive genes 
from méthylation (43).
ation
The absence of P-cadherin expression may refi not a
transcriptional alteration but the loss of this basal cell population 
during cancer formation. Our observation that intermittant, scat­
tered P-cadherin-positive basal cells remain in specimens con­
taining PIN, considered a premalignanl lesion (25), might sug­
gest that these cells are gradually lost during tumor formation. In 
vivo, other basal cell markers, notably the C a 1 -i 
cell-cell adhesion C-CAM, demonstrates this
of loss of expression in the progression to PIN and frank 
prostate cancer (44). Other basal cell epithelial genes that are not 
widely investigated (14, 39); however, less is known of the expressed in the histological prostate cancer includes the high 
factors involved in P-cadherin expression. Mouse promoter molecular weight cytokeratins 5, 10, and 11 (45). This body of 
studies have suggested that highly complex combinations of evidence would support the hypothesis that prostate cancers 
elements in the promoter and second intron regulate transcrip- originate from a morphologically intermediate epithelial cell 
tion in a cell type-specific fashion (27). Our sequence data rather than a basal cell (30, 32).
reveal that the P-cadherin and E-cadherin promoters contain P-cadherin represents a basal epithelial marker in normal
similar putative regulatory elements, as well as other related prostate tissues that is inherently lost during the formation of 
structural features, such as the presence of Alu repeats and prostate cancer. All 25 of the prostate cancers examined were
B2/E2 repetitive elements. E2 elements are believed to be im-
ant in tissue- (40). ar to the
immunohistochemically negative for P-cadherin, and therefore 
P-cadherin provides a useful marker for the histological diag-
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nos is o f  prostate cancer. T he m olecu lar  m e c h a n ism s  u n d er ly in g  17. Graff, J. R., Herman, J. G., Lapidus, R. G., Chopra, H., Xu, R., 
the regulation o f  the E-cadherin g e n e  are c o m p le x ,  and s im i-  Jarrard, D. F., Isaacs, W. B., Pitha, P. M„ Davidson, N. E„ and Baylin,
*"i. * * * %  V I *  < • • t I t  \  f  i  1 < 1 1 . *  I
larly, our promoter sequence data for P-cadherin suggest that 
many putative regulatory mechanisms may be important. The 
role that P-cadherin plays in the transition from basal cell to 
secretory epithelial cell and alterations in this process in prostate 
carcinogenesis remain important questions for further investi­
gation.
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